Sort
85,873 grants matching “alzheimers”
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINE
$810,923Jeanne Mandelblatt · Georgetown University · R01 · FY2009 · CA
The Role of Visit Audio Recordings in Triadic Dementia Care
$810,911Paul James Barr · Dartmouth College · R01 · FY2023 · AG
Understanding and Improving Surgical Decision-Making for Persons Living with Dementia, their Family Caregivers, and their Providers: A Mixed Methods Study
$810,880Joel S. Weissman · Brigham And Women'S Hospital · R01 · FY2021 · AG
Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support
$810,828Suneel Ismail Sheikh · Aster Labs, Inc. · R44 · FY2017 · AG
The Hospice Advanced dementia Symptom Management and Quality of Life Trial (HAS-QOL)
$810,745Abraham Aizer Brody · New York University · R61 · FY2018 · AG
APOE Genotype Mediated Effects on Alzheimer Disease Risk and Mechanisms
$810,698Lindsay A. Farrer · Boston University Medical Campus · U01 · FY2024 · AG
UAS-CLEAR: A new nationally representative longitudinal study of caregiving experiences and well-being across the lifecourse
$810,685Kira S Birditt · University Of Michigan At Ann Arbor · R01 · FY2024 · AG
Cognitive and Physical Exercise to Improve Outcomes after Surgery in the Elderly
$810,661Christopher Hughes · Vanderbilt University Medical Center · R01 · FY2024 · AG
Partnership in Implementation Science for Geriatric Mental Health (PRISM)
$810,639Hongtu Chen · Brigham And Women'S Hospital · U19 · FY2017 · MH
Improving Outcomes for Family Caregivers and Older Adults with Complex Conditions: The Adult Day Service Plus Program
$810,638Laura N. Gitlin · Johns Hopkins University · R01 · FY2016 · AG
Revealing the roles of HSV1 lytic and latent transcripts in AD pathogenesis and therapy
$810,619Michael G Rosenfeld · University Of California, San Diego · R01 · FY2022 · AG
Off-the-shelf CAR-Engineered Macrophage Therapy for Alzheimerâs Disease
$810,596Martin Joseph Sadowski · New York University School Of Medicine · R61 · FY2025 · AG
Development of completely automated quality control procedures for 4 PET Imaging tracers that will increase production throughput and lead to expanded diversity of PET imaging available to patients.
$810,570Arkadij Elizarov · Trace-Ability, Inc. · R44 · FY2020 · MH
Quantitative systems pharmacology and translational study of pramlintide for Alzheimer's disease
$810,558Wei Qiao Qiu · Boston University Medical Campus · R56 · FY2018 · AG
Social Networks in Nurse Practitioner Teams Caring for Patients with Dementia and Impact on Racial and Ethnic Disparities
$810,548Lusine Poghosyan · Columbia University Health Sciences · R01 · FY2024 · AG
Characterizing Cognitive Decline in Late Life Depression: The ADNI-D Project
$810,454Robert Scott Mackin · University Of California, San Francisco · R01 · FY2025 · MH
APOE4 dependent regulation of CSF Complement Pathway Activation in the development of Alzheimer's Disease
$810,435Miles Berger · Duke University · R01 · FY2022 · AG
Mechanisms of Adherence to Light Intensity Physical Activity to Prevent Alzheimer's Disease and Related Dementias
$810,386Jonathan G. Hakun · Pennsylvania State Univ Hershey Med Ctr · R33 · FY2023 · AG
Maladaptive antiviral pathways in Alzheimer's disease
$810,371Li Gan · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · AG
Investigating Resistance and Resilience Mechanisms in Alzheimerâs Disease
$810,339Prashanthi Vemuri · Mayo Clinic Rochester · R01 · FY2023 · AG
Subjective Cognitive Decline in OIder Adults
$810,338Katherine A. Gifford · Vanderbilt University Medical Center · R01 · FY2022 · AG
Natural Language Processing and Automated Speech Recognition to Identify Older Adults with Cognitive Impairment
$810,274Alex D. Federman · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · AG
Modulation effects of Baduanjin mind-body exercise on subjective cognitive decline
$810,269Jian Kong · Massachusetts General Hospital · R01 · FY2021 · AG
Development of sensitive PET tracers of pan-Amyloid-beta species for Alzheimer's disease
$810,197Chongzhao Ran · Massachusetts General Hospital · R01 · FY2025 · AG
Preclinical assessment of GCPII inhibitors for cognition and tau pathology
$810,149Amy F.t. Arnsten · Yale University · R01 · FY2019 · AG